Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Director | June 08, 2023 | June 12, 2023 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 10, 2026 | June 12, 2026 |
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Director | June 26, 2019 | June 27, 2019 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director | May 24, 2006 | May 25, 2006 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-06-08 | Direct | 6,500 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The shares subject to the options shall vest 25% every quarter after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest 25% every quarter after the grant date.
LIGAND PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,969 |
Ending reported balance
After 2026-06-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-10 · Sale · Disposed 257 · Balance 31,303 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-06-10 · Sale · Disposed 232 · Balance 31,071 F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-06-10 · Sale · Disposed 697 · Balance 30,374 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-06-10 · Sale · Disposed 3,405 · Balance 26,969 F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Larimar Therapeutics, Inc.
Report date June 26, 2019 · Filed June 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2029-06-26 | Direct | 27,000 |
Reported balance
After 2019-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-26 · Grant · Acquired 27,000 · Balance 27,000 F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.
THERMO FISHER SCIENTIFIC INC.
Report date May 24, 2006 · Filed May 25, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2013-05-24 | Direct | 10,500 |
Reported balance
After 2006-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-05-24 · Grant · Acquired 10,500 · Balance 10,500 F1: The option vests in three equal annual installments beginning on May 24, 2007. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments beginning on May 24, 2007.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date October 15, 2007 · Filed October 17, 2007
Section 16 reporting ended · disclosed 2007-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 57,875 |
Reported balance
After 2007-10-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2007-10-15 · Grant · Acquired 214 · Balance 57,875 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 7, 2019 22:46 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000104 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,284 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 19:01 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantCommon Stock | 10,844 | $4.38 | $47,496.72 |
DisclosureSEC source: 0000899243-19-002065 · doc4.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,376 F1 · kind: The common stock was acquired in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Restricted Stock Unit Award and the restrictions lapse over a period of one year starting January 1, 2019 on a quarterly basis in arrears. Each restricted stock unit represents a contingent right to receive one share of Zafgen, Inc. common stock. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,335 | $0.00 Strike: $12.53 | $0.00 |
DisclosureSEC source: 0000886163-18-000131 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,335 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,335 | $254.96 | $850,291.93 |
DisclosureSEC source: 0000886163-18-000131 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,449 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.09, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 23:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,335 | $12.53 | $41,787.55 |
DisclosureSEC source: 0000886163-18-000131 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $76.77 | $0.00 |
DisclosureSEC source: 0000899243-18-017603 · doc4.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017603 · doc4.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,449 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jul 3, 2018 22:39 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $195.91 | $0.00 |
DisclosureSEC source: 0000886163-18-000096 · edgardoc.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 17:35 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000899243-18-015554 · doc4.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 6, 2019 or the date of the 2019 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 23:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $12.53 | $0.00 |
DisclosureSEC source: 0000886163-18-000080 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335 Underlying: Common Stock · 4,000 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 23:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,000 | $194.51 | $778,038.80 |
DisclosureSEC source: 0000886163-18-000080 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,956 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.23 to $199.07, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 23:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,000 | $12.53 | $50,120.00 |
DisclosureSEC source: 0000886163-18-000080 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,335 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000886163-18-000042 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,335 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,335 | $160.90 | $536,603.83 |
DisclosureSEC source: 0000886163-18-000042 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,956 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.03 to $161.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,335 | $10.12 | $33,750.20 |
DisclosureSEC source: 0000886163-18-000042 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 17:01 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantCommon Stock | 9,169 | $5.18 | $47,495.42 |
DisclosureSEC source: 0000899243-18-000595 · doc4.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,532 F1 · shares: The common stock was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Restricted Stock Agreement and the restrictions lapse over a period of one year starting January 1, 2018 on a quarterly basis in arrears. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 00:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $10.12 | $0.00 |
DisclosureSEC source: 0000886163-17-000140 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335 Underlying: Common Stock · 4,000 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and will fully vest on the first anniversary of the grant date. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 00:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,000 | $139.79 | $559,160.00 |
DisclosureSEC source: 0000886163-17-000140 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,956 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.75 to $139.79, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 00:19 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,000 | $10.12 | $40,480.00 |
DisclosureSEC source: 0000886163-17-000140 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 16:09 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000899243-17-017077 · doc4.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 21, 2018 or the date of the 2018 annual meeting of stockholders, subject to the director's continued service on the board of directors. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,456 | $113.50 Strike: $113.50 | $278,756.00 |
DisclosureSEC source: 0000886163-17-000073 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,456 Underlying: Common Stock · 2,456 shares Expires 2027-05-25 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000073 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,956 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017 Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 20:07 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantCommon Stock | 11,363 | $4.18 | $47,497.34 |
DisclosureSEC source: 0000899243-17-004091 · doc4.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,363 F1 · shares: The common stock was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Restricted Stock Agreement and the restrictions lapse over a period of one year starting January 1, 2017 on a quarterly basis in arrears. Read SEC document |
| October 15, 2007 Filed Oct 17, 2007 13:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 214 | $25.00 | $5,350.00 |
DisclosureSEC source: 0000078003-07-000282 · lam1615.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,875 Underlying: Common Stock · 214 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 28, 2007 Filed Oct 2, 2007 16:42 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 232 | $24.43 | $5,667.76 |
DisclosureSEC source: 0000078003-07-000264 · lam1598.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,661 Underlying: Common Stock · 232 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 14, 2007 Filed Sep 17, 2007 22:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 226 | $24.29 | $5,489.54 |
DisclosureSEC source: 0000078003-07-000236 · lam1583.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,429 Underlying: Common Stock · 226 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2007 Filed Sep 4, 2007 17:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 185 | $24.84 | $4,595.40 |
DisclosureSEC source: 0000078003-07-000221 · lam1573.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,203 Underlying: Common Stock · 185 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2007 Filed Aug 17, 2007 12:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 910 | $23.53 | $21,412.30 |
DisclosureSEC source: 0000078003-07-000208 · lam1564.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,018 Underlying: Common Stock · 910 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2007 Filed Aug 1, 2007 21:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 239 | $23.51 | $5,618.89 |
DisclosureSEC source: 0000078003-07-000186 · lam1555.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,108 Underlying: Common Stock · 239 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2007 Filed Jul 17, 2007 14:47 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 215 | $25.91 | $5,570.65 |
DisclosureSEC source: 0000078003-07-000175 · lam1546.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,869 Underlying: Common Stock · 215 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 29, 2007 Filed Jul 3, 2007 14:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 217 | $25.57 | $5,548.69 |
DisclosureSEC source: 0000078003-07-000165 · lam1534.xml · derivative · entry 4 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,654 Underlying: Common Stock · 217 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 29, 2007 Filed Jul 3, 2007 14:45 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 6,264 | $25.57 | $160,170.48 |
DisclosureSEC source: 0000078003-07-000165 · lam1534.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,190 Read SEC document |
| June 15, 2007 Filed Jun 18, 2007 20:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 212 | $26.47 | $5,611.64 |
DisclosureSEC source: 0000078003-07-000138 · lam1521.xml · derivative · entry 5 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,437 Underlying: Common Stock · 212 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2007 Filed Jun 18, 2007 20:38 UTC | PFIZER INC PFE · Entity 2863 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-07-000138 · lam1521.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,454 Read SEC document |
| June 15, 2007 Filed Jun 18, 2007 20:38 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 36,066 | $26.48 | $955,027.68 |
DisclosureSEC source: 0000078003-07-000138 · lam1521.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,454 Read SEC document |
| May 31, 2007 Filed Jun 1, 2007 18:36 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 192 | $27.49 | $5,278.08 |
DisclosureSEC source: 0000078003-07-000127 · lam1515.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,225 Underlying: Common Stock · 192 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2007 Filed May 16, 2007 19:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 777 | $27.10 | $21,056.70 |
DisclosureSEC source: 0000078003-07-000117 · lam1506.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,033 Underlying: Common Stock · 777 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2007 Filed May 1, 2007 20:41 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 207 | $26.46 | $5,477.22 |
DisclosureSEC source: 0000078003-07-000097 · lam1495.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,256 Underlying: Common Stock · 207 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 13, 2007 Filed Apr 17, 2007 15:22 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 198 | $26.67 | $5,280.66 |
DisclosureSEC source: 0000078003-07-000070 · lam1473.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,049 Underlying: Common Stock · 198 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 30, 2007 Filed Apr 3, 2007 15:28 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 205 | $25.26 | $5,178.30 |
DisclosureSEC source: 0000078003-07-000061 · lam1459.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,851 Underlying: Common Stock · 205 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 23, 2007 Filed Mar 27, 2007 20:06 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 13,710 | $25.66 | $351,798.60 |
DisclosureSEC source: 0000078003-07-000050 · lam1451.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,822 Read SEC document |
| March 15, 2007 Filed Mar 19, 2007 18:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 3,927 | $24.99 | $98,135.73 |
DisclosureSEC source: 0000078003-07-000042 · lam1442.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,646 Underlying: Common Stock · 3,927 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 22:12 UTC | PFIZER INC PFE · Entity 2863 | GrantEmployee Stock Option (right to buy) · Derivative | 177,500 | $0.00 Strike: $25.87 | $0.00 |
DisclosureSEC source: 0000078003-07-000028 · lam1432.xml · derivative · entry 6 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,500 Underlying: Common Stock · 177,500 shares Expires 2017-02-21 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 22:12 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 19,974 | $25.87 | $516,727.38 |
DisclosureSEC source: 0000078003-07-000028 · lam1432.xml · nonDerivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,158 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 22:12 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 56,040 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-07-000028 · lam1432.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,132 F2 · shares: The reported transaction constitutes the earn-out of Performance-Contingent Shares. Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 22:12 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 17,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-07-000028 · lam1432.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,092 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| February 07, 2007 Filed Feb 8, 2007 20:40 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,800 | $0.00 Strike: $18.35 | $0.00 |
DisclosureSEC source: 0000078003-07-000019 · lam1423.xml · derivative · entry 5 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,800 shares Expires 2007-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in 5 equal annual installments beginning on August 28,1998. Read SEC document |
| February 07, 2007 Filed Feb 8, 2007 20:40 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 13,800 | $26.54 | $366,252.00 |
DisclosureSEC source: 0000078003-07-000019 · lam1423.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,101 Read SEC document |
| February 07, 2007 Filed Feb 8, 2007 20:40 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 13,800 | $18.35 | $253,230.00 |
DisclosureSEC source: 0000078003-07-000019 · lam1423.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2006 Filed Jan 3, 2007 23:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 200 | $25.90 | $5,180.00 |
DisclosureSEC source: 0000078003-07-000008 · lam1409.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,161 Underlying: Common Stock · 200 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and, subject to certain conditions, may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.